Evidence map›Paper›PMID 35862024›Full record

Trial reportCirculation research2022

Association of Physical Activity With Bioactive Lipids and Cardiovascular Events.

Rosangela A Hoshi, Yanyan Liu, Heike Luttmann-Gibson, Saumya Tiwari, Franco Giulianini, Allen M Andres, Jeramie D Watrous, Nancy R Cook, Karen H Costenbader, Olivia I Okereke and 10 more

2 registry-linked trialsOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00239681 phase3terminatednot on this map

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein

TypeinterventionalSponsorAstraZenecaRan2003 to 2008Enrolled17,802ConditionsElevated High-sensitivity C-Reactive Protein (hsCRP)ArmsRosuvastatin, Placebo
NCT01169259 phase3active not recruitingnot on this map

Vitamin D and Omega-3 Trial (VITAL)

TypeinterventionalSponsorBrigham and Women's HospitalRan2010 to 2026Enrolled25,871ConditionsCancer, Cardiovascular DiseaseArmsvitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, Fish oil placebo
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Exercise benefits in metabolism on cardiovascular disease.Frontiers in cardiovascular medicine · 2026
    Review
  5. Physical activity, metabolites, and breast cancer associations.Journal of the National Cancer Institute · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Rosangela A Hoshi *Center for Lipid Metabolomics, Division of Preventive Medicine, Division of Cardiovascular Medicine (R.A.H., Y.L., H.L.-G., P.M.R., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-4034-0451
Yanyan Liu *Center for Lipid Metabolomics, Division of Preventive Medicine, Division of Cardiovascular Medicine (R.A.H., Y.L., H.L.-G., P.M.R., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Heike Luttmann-GibsonCenter for Lipid Metabolomics, Division of Preventive Medicine, Division of Cardiovascular Medicine (R.A.H., Y.L., H.L.-G., P.M.R., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-1265-9190
Saumya TiwariDepartment of Pharmacology, University of California San Diego, La Jolla (S.T., A.M.A., J.D.W.).ORCID 0000-0001-5148-6539
Franco GiulianiniDivision of Preventive Medicine (R.A.H., Y.L., H.L.-G., F.G., N.R.C., P.M.R., J.E.M., I.-M.L., M.V., T.C., D.I.C., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Allen M AndresDepartment of Pharmacology, University of California San Diego, La Jolla (S.T., A.M.A., J.D.W.).
Jeramie D WatrousDepartment of Pharmacology, University of California San Diego, La Jolla (S.T., A.M.A., J.D.W.).
Nancy R CookDivision of Preventive Medicine (R.A.H., Y.L., H.L.-G., F.G., N.R.C., P.M.R., J.E.M., I.-M.L., M.V., T.C., D.I.C., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-9705-0842
Karen H CostenbaderDivision of Rheumatology, Inflammation and Immunity (K.H.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Olivia I OkerekeDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (H.L.-G., O.I.O., J.E.M., I.-M.L., M.J.).
Paul M RidkerCenter for Lipid Metabolomics, Division of Preventive Medicine, Division of Cardiovascular Medicine (R.A.H., Y.L., H.L.-G., P.M.R., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
JoAnn E MansonDivision of Preventive Medicine (R.A.H., Y.L., H.L.-G., F.G., N.R.C., P.M.R., J.E.M., I.-M.L., M.V., T.C., D.I.C., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-9426-7595
I-Min LeeDivision of Preventive Medicine (R.A.H., Y.L., H.L.-G., F.G., N.R.C., P.M.R., J.E.M., I.-M.L., M.V., T.C., D.I.C., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-1083-6907
Manickavasagar VinayagamoorthyDivision of Preventive Medicine (R.A.H., Y.L., H.L.-G., F.G., N.R.C., P.M.R., J.E.M., I.-M.L., M.V., T.C., D.I.C., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-0983-3215
Susan ChengSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (S.C.).ORCID 0000-0002-4977-036X
Trisha CopelandDivision of Preventive Medicine (R.A.H., Y.L., H.L.-G., F.G., N.R.C., P.M.R., J.E.M., I.-M.L., M.V., T.C., D.I.C., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Mohit Jain *Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (H.L.-G., O.I.O., J.E.M., I.-M.L., M.J.).
Daniel I Chasman *Division of Preventive Medicine (R.A.H., Y.L., H.L.-G., F.G., N.R.C., P.M.R., J.E.M., I.-M.L., M.V., T.C., D.I.C., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-3357-0862
Olga V Demler *Center for Lipid Metabolomics, Division of Preventive Medicine, Division of Cardiovascular Medicine (R.A.H., Y.L., H.L.-G., P.M.R., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-3355-3210
Samia Mora *Center for Lipid Metabolomics, Division of Preventive Medicine, Division of Cardiovascular Medicine (R.A.H., Y.L., H.L.-G., P.M.R., O.V.D., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0001-6283-0980
Brigham and Women's Hospital · USUniversity of California San Diego · USHarvard University · USCedars-Sinai Medical Center · US

Funding

VITamin D and omegA-3 triaL (VITAL)U01CA138962 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., MANSON, JOANN ELISABETH · 2009 to 2014
$23.6M
The VITamin D and OmegA-3 TriaL (VITAL)R01CA138962 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., MANSON, JOANN ELISABETH · 2015 to 2019
$20.9M
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)U54AG065141 · NIA · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL, CHENG, SUSAN · 2020 to 2024
$8.7M
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaLR01MH091448 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI OKEREKE, OLIVIA IFEOMA · 2010 to 2019
$6.5M
Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Joint PainR01AR059086 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2010 to 2021
$5.4M
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-UpR01AT011729 · NCCIH · BRIGHAM AND WOMEN'S HOSPITAL · PI Jun Li, JoAnn Elisabeth Manson · 2021 to 2026
$5.2M
Women's Health Study: Infrastructure support for continued cohort follow-upU01CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2019 to 2023
$4.0M
Mediators of Systemic Inflammation and Heart Failure Risk in the CommunityR01HL143227 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2019 to 2022
$3.3M
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid PathwaysR01HL134811 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2017 to 2020
$3.0M
Circulating plasma metabolites, diet, and risk of type 2 diabetesR01DK112940 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HU, FRANK B, MORA, SAMIA · 2018 to 2021
$2.9M
Inflammatory Mediators, Cardiovascular Health, and Longevity in WomenR01HL134168 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2016 to 2019
$1.6M
VITAL-DEP (VITamin D and OmegA 3 TriaL-Depression Endpoint Prevention)R56MH091448 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI OKEREKE, OLIVIA IFEOMA · 2022 to 2022
$1.3M
NCCIH NIH HHS R01 AT011729NCI NIH HHS R01 CA138962NCI NIH HHS U01 CA138962NCI NIH HHS U01 CA182913NHLBI NIH HHS K01 HL135342NHLBI NIH HHS K24 HL136852NHLBI NIH HHS R01 HL134168NHLBI NIH HHS R01 HL134811NHLBI NIH HHS R01 HL143227NHLBI NIH HHS R21 HL167173NIAMS NIH HHS R01 AR059086NIA NIH HHS U54 AG065141NIDDK NIH HHS R01 DK112940NIMH NIH HHS R01 MH091448NIMH NIH HHS R56 MH091448
6 · The paper itself

Abstract

backgroundTo clarify the mechanisms underlying physical activity (PA)-related cardioprotection, we examined the association of PA with plasma bioactive lipids (BALs) and cardiovascular disease (CVD) events. We additionally performed genome-wide associations.

methodsPA-bioactive lipid associations were examined in VITAL (VITamin D and OmegA-3 TriaL)-clinical translational science center (REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01169259; N=1032) and validated in JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)-NC (REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00239681; N=589), using linear models adjusted for age, sex, race, low-density lipoprotein-cholesterol, total-C, and smoking. Significant BALs were carried over to examine associations with incident CVD in 2 nested CVD case-control studies: VITAL-CVD (741 case-control pairs) and JUPITER-CVD (415 case-control pairs; validation).

resultsWe detected 145 PA-bioactive lipid validated associations (false discovery rate <0.1). Annotations were found for 6 of these BALs: 12,13-diHOME, 9,10-diHOME, lysoPC(15:0), oxymorphone-3b-D-glucuronide, cortisone, and oleoyl-glycerol. Genetic analysis within JUPITER-NC showed associations of 32 PA-related BALs with 22 single-nucleotide polymorphisms. From PA-related BALs, 12 are associated with CVD.

conclusionsWe identified a PA-related bioactive lipidome profile out of which 12 BALs also had opposite associations with incident CVD events.

Indexed as

Cardiovascular DiseasesExerciseHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLHumansRisk FactorsRosuvastatin CalciumCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin Calciumbioactive lipidscardioprotectionexercisegenetic analysismetabolism

Identifiers

PMID35862024
PMCPMC9357171
OpenAlexW4285796198

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.